Clinical Trial: A Phase II Study of Benmelstobart + Anlotinib + Chemotherapy as First-Line Treatment for LCNEC and EP-NEC

U.S., April 4 -- ClinicalTrials.gov registry received information related to the study (NCT07510594) titled 'A Phase II Study of Benmelstobart + Anlotinib + Chemotherapy as First-Line Treatment for LCNEC and EP-NEC' on Feb. 03.

Brief Summary: To explore the Objective Response Rate (ORR) of Benmelstobart combined with Anlotinib and chemotherapy as first-line treatment for large-cell neuroendocrine carcinoma of the lung (LCNEC) and extrapulmonary neuroendocrine carcinoma (EP-NEC)

Study Start Date: May 01

Study Type: INTERVENTIONAL

Condition: Large-Cell Neuroendocrine Carcinoma of the Lung Extrapulmonary Neuroendocrine Carcinoma

Intervention: DRUG: Benmelstobart+ Anlotinib+ Platinum + Etoposide

Treatment phase (intensive combination tr...